FIELD: pharmaceutics.
SUBSTANCE: invention relates to new isoxazoles of formula (I) or pharmaceutically acceptable salts thereof, having agonistic activity against the farnesoid FXRreceptor. In this formula, R1 and R2 are independently selected from the group consisting of H, halogen and CF 3, provided that R1 and R2 are not H at the same time; R3 is C1-C3 alkyl; n is an integer selected from 1, 2 and 3; R4 is selected from the group consisting of phenyl unsubstituted or substituted with one R5 and biphenyl unsubstituted or substituted with one R5 ; R5 is selected from the group consisting of COOR6, CN, hydroxy-C1-C3 alkyl, C1-C3 alkyl-O-phenyl unsubstituted or substituted with one R7, and C1-C3 alkyl-O-biphenyl , unsubstituted or substituted with one R7; R6 is selected from the group consisting of H and C1-C3 alkyl, and R7 is selected from the group consisting of COOR6, CN and hydroxy-C1-C3 alkyl; provided that the compound is not 4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)benzoic acid. The invention also relates to a pharmaceutical composition containing isoxazole formula (I) and its use as a drug for the prevention and/or treatment of FXR-dependent diseases.
EFFECT: drug for the prevention and/or treatment of FXR-dependent diseases.
9 cl, 1 tbl, 6 ex
I. 
| Title | Year | Author | Number |
|---|---|---|---|
| FURIN INHIBITORS | 2019 |
|
RU2799824C2 |
| DERIVATIVES OF PYRIDINE AND APPLICATION THEREOF AGAINST MICROBACTERIA | 2015 |
|
RU2664587C1 |
| USE OF TRICYCLIC DERIVATIVES OF 1,4-DIHYDRO-1,4-DIOXO-1H-NAPHTHALENE AND ITS NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND DERIVATIVES OF SUBSTITUTED NAPHTHALENES AS INTERMEDIATE COMPOUNDS | 1996 |
|
RU2178791C2 |
| LIGANDS FOR AGGREGATED MOLECULES OF TAU-PROTEIN | 2009 |
|
RU2518892C2 |
| IMIDAZOPIRASOTHINES AS PDE1 INHIBITORS | 2016 |
|
RU2712219C2 |
| DERIVATIVES OF GALANTHAMINE, METHOD FOR THEIR PREPARING, MEDICINAL AGENT BASED ON THEREOF AND METHOD FOR ITS PREPARING | 2001 |
|
RU2241001C2 |
| DERIVATIVES OF AZA-ADAMANTANES AND THEIR APPLICATION | 2012 |
|
RU2672468C1 |
| CETP INHIBITORS | 2006 |
|
RU2513107C2 |
| HETEROCYCLIC MUSCARINIC AGONISTS AND COMPOSITIONS, THEIR USING AND METHODS FOR TREATMENT | 2002 |
|
RU2292346C2 |
| ERBB/BTK INHIBITORS | 2019 |
|
RU2764069C1 |
